ES3041322T3 - Novel mek-inhibitor for the treatment of viral and bacterial infections - Google Patents

Novel mek-inhibitor for the treatment of viral and bacterial infections

Info

Publication number
ES3041322T3
ES3041322T3 ES21185183T ES21185183T ES3041322T3 ES 3041322 T3 ES3041322 T3 ES 3041322T3 ES 21185183 T ES21185183 T ES 21185183T ES 21185183 T ES21185183 T ES 21185183T ES 3041322 T3 ES3041322 T3 ES 3041322T3
Authority
ES
Spain
Prior art keywords
pharmaceutically acceptable
acceptable salt
bacterial
virus
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21185183T
Other languages
English (en)
Spanish (es)
Inventor
Stephan Ludwig
Oliver Planz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atriva Therapeutics GmbH
Original Assignee
Atriva Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atriva Therapeutics GmbH filed Critical Atriva Therapeutics GmbH
Application granted granted Critical
Publication of ES3041322T3 publication Critical patent/ES3041322T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES21185183T 2017-10-17 2018-10-17 Novel mek-inhibitor for the treatment of viral and bacterial infections Active ES3041322T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LU100487 2017-10-17

Publications (1)

Publication Number Publication Date
ES3041322T3 true ES3041322T3 (en) 2025-11-11

Family

ID=60484427

Family Applications (2)

Application Number Title Priority Date Filing Date
ES21185183T Active ES3041322T3 (en) 2017-10-17 2018-10-17 Novel mek-inhibitor for the treatment of viral and bacterial infections
ES18800045T Active ES2883639T3 (es) 2017-10-17 2018-10-17 Nuevo inhibidor de MEK para el tratamiento de infecciones víricas y bacterianas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18800045T Active ES2883639T3 (es) 2017-10-17 2018-10-17 Nuevo inhibidor de MEK para el tratamiento de infecciones víricas y bacterianas

Country Status (21)

Country Link
US (2) US11903917B2 (OSRAM)
EP (2) EP3697405B1 (OSRAM)
JP (3) JP7227967B2 (OSRAM)
KR (1) KR102848960B1 (OSRAM)
CN (2) CN111479566B (OSRAM)
AU (2) AU2018351475A1 (OSRAM)
BR (1) BR112020007442A2 (OSRAM)
CA (1) CA3078424A1 (OSRAM)
CY (1) CY1124507T1 (OSRAM)
DK (1) DK3697405T3 (OSRAM)
EA (1) EA202090693A1 (OSRAM)
ES (2) ES3041322T3 (OSRAM)
HR (1) HRP20211252T1 (OSRAM)
HU (1) HUE055738T2 (OSRAM)
LT (1) LT3697405T (OSRAM)
MX (2) MX2020003473A (OSRAM)
PL (1) PL3697405T3 (OSRAM)
PT (1) PT3697405T (OSRAM)
SI (1) SI3697405T1 (OSRAM)
WO (1) WO2019076947A1 (OSRAM)
ZA (1) ZA202002069B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3697405T (pt) * 2017-10-17 2021-08-27 Atriva Therapeutics Gmbh Novo inibidor de mek para o tratamento de infeções virais e bacterianas
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
CN114667138A (zh) * 2019-08-27 2022-06-24 归属疗法有限公司 Mek抑制剂与帽状结构依赖型核酸内切酶抑制剂的组合
KR20220079573A (ko) * 2019-10-08 2022-06-13 아트리바 테라퓨틱스 게엠베하 한타바이러스 감염의 치료를 위한 mek 억제제
EP3912623B1 (en) * 2020-05-20 2024-07-31 Atriva Therapeutics GmbH Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm
CN112957361B (zh) * 2021-03-24 2022-07-29 中国科学院武汉病毒研究所 曲美替尼在制备抗沙粒病毒的抗病毒制剂中的应用
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
HUP0104933A3 (en) * 1999-01-07 2003-12-29 Warner Lambert Co Antiviral method using mek inhibitors
PL352684A1 (pl) 1999-07-16 2003-09-08 Warner-Lambert Company Sposób leczenia chronicznego bólu z użyciem inhibitorów MEK
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
JP2005515253A (ja) 2002-01-23 2005-05-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｎ−（４−置換フェニル）−アントラニル酸ヒドロキサメートエステル
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
JP2007055983A (ja) * 2005-08-26 2007-03-08 Tokyo Univ Of Science 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤
KR20130113430A (ko) 2010-08-05 2013-10-15 케이스 웨스턴 리저브 유니버시티 신경 연결의 발달 장애에 대한 ｅｒｋ 억제제
JP6294889B2 (ja) * 2012-10-08 2018-03-14 アトリバ セラピューティクス ゲーエムベーハー ウイルス疾患の処置におけるｍｅｋ阻害物質
CN113398271A (zh) 2014-05-16 2021-09-17 归属疗法有限公司 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略
PT3697405T (pt) * 2017-10-17 2021-08-27 Atriva Therapeutics Gmbh Novo inibidor de mek para o tratamento de infeções virais e bacterianas
KR20220079573A (ko) 2019-10-08 2022-06-13 아트리바 테라퓨틱스 게엠베하 한타바이러스 감염의 치료를 위한 mek 억제제
EP3912623B1 (en) 2020-05-20 2024-07-31 Atriva Therapeutics GmbH Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm

Also Published As

Publication number Publication date
EP3697405A1 (en) 2020-08-26
PL3697405T3 (pl) 2021-12-13
CN111479566B (zh) 2024-05-07
KR102848960B1 (ko) 2025-08-21
US11903917B2 (en) 2024-02-20
WO2019076947A1 (en) 2019-04-25
CN118141795A (zh) 2024-06-07
MX2020003473A (es) 2020-10-01
CN111479566A (zh) 2020-07-31
JP7227967B2 (ja) 2023-02-22
EP3697405B1 (en) 2021-07-14
AU2018351475A1 (en) 2020-04-30
JP2025031917A (ja) 2025-03-07
PT3697405T (pt) 2021-08-27
JP2020537659A (ja) 2020-12-24
US20200289445A1 (en) 2020-09-17
EP3973960B1 (en) 2025-09-03
HRP20211252T1 (hr) 2021-11-12
EA202090693A1 (ru) 2020-10-19
BR112020007442A2 (pt) 2020-10-27
LT3697405T (lt) 2021-10-25
ZA202002069B (en) 2021-10-27
JP7618276B2 (ja) 2025-01-21
DK3697405T3 (da) 2021-08-23
CA3078424A1 (en) 2019-04-25
AU2024205853A1 (en) 2024-09-05
ES2883639T3 (es) 2021-12-09
EP3973960C0 (en) 2025-09-03
EP3973960A1 (en) 2022-03-30
CY1124507T1 (el) 2022-07-22
SI3697405T1 (sl) 2021-11-30
KR20200072499A (ko) 2020-06-22
MX2022016066A (es) 2023-02-02
JP2023058631A (ja) 2023-04-25
US20240245637A1 (en) 2024-07-25
HUE055738T2 (hu) 2021-12-28

Similar Documents

Publication Publication Date Title
ES3041322T3 (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
US11135263B2 (en) Novel-anti-infective strategy against influenza virus and S. aureus coinfections
ES3012533T3 (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
EA047137B1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
HK40029715B (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
HK40029715A (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
Barlow et al. Infectious diseases and tropical medicine